GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations11,813.113,321.716,982.517,736.6
Other Income840.0113.7460.6499.9
Total Income12,653.113,435.517,443.118,236.5
Expenses
+ Cost of Materials Consumed3,157.83,001.32,961.52,830.1
+ Purchases of Stock-in-Trade1,451.21,566.02,396.62,476.1
+ Changes in Inventories-195.6-213.9-610.6-328.4
+ Employee Benefit Expense2,868.13,022.13,577.93,749.8
+ Finance Costs516.0207.1208.7204.5
+ Depreciation & Amortisation581.9486.0573.5616.7
+ Other Expenses3,336.33,595.04,084.84,212.4
Total Expenses11,715.611,663.413,192.313,761.1
EBITDA1,195.32,351.44,572.44,796.7
EBIT613.41,865.43,998.94,180.0
Profit
PBT before Exceptional Items937.51,772.04,250.84,475.4
+ Exceptional Items-901.0-372.8-2,266.1-1,942.9
Pretax Income36.51,399.21,984.72,532.6
+ Current Tax1,115.6382.3676.5778.0
+ Deferred Tax751.8-30.3-53.7-43.2
Tax Expense1,867.3352.1622.8734.8
Net Income-1,433.51,047.11,362.01,797.8
+ Net Income — Continuing Ops-1,830.91,047.11,362.01,797.8
+ Net Income — Discontinued Ops397.30.00.00.0
+ Other Comprehensive Income-65.664.2414.4353.5
Total Comprehensive Income-1,499.11,111.31,776.32,151.3
Net Income to Common-1,501.71,047.10.11,496.4
Minority Interest68.10.01,361.9301.4
Per Share
Basic EPS-53.2237.1148.2663.71
Diluted EPS-53.2237.1048.2463.69
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax532.70.00.00.0
+ Tax — Discontinued Operations135.40.00.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income64.2414.4353.5
+ Items NOT to be Reclassified to P&L-21.9-12.0-9.4-9.5
+ Tax on Items NOT to be Reclassified-3.82.42.4
+ Tax on Items NOT to be Reclassified — alt tag-4.3
+ Items to be Reclassified to P&L-39.986.7483.2426.5
+ Tax on Items to be Reclassified14.457.161.1
+ Tax on Items to be Reclassified — alt tag8.0
Comprehensive Income — Owners of Parent-1,566.31,111.30.11,661.3
Comprehensive Income — Non-controlling Interests67.20.01,776.3490.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-67.3037.1148.2663.71
Diluted EPS — Continuing Operations-67.3037.1048.2463.69
Basic EPS — Discontinued Operations14.080.000.000.00
Diluted EPS — Discontinued Operations14.080.000.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit7,399.78,968.412,235.012,758.9
Gross Margin %62.6467.3272.0471.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)937.51,772.04,250.84,475.4
− Exceptional Items (reconciliation)-901.0-372.8-2,266.1-1,942.9
Net Income Adj (tax-effected)-1,073.11,326.22,917.03,177.0
EPS Adj-39.8447.00103.36112.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital28.228.228.228.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.